Linzess
Evidence Grade A — Regulatory approved. 453 published studies. 57 registered clinical trials.
Loading...
Linaclotide (sold as Linzess) is a daily oral capsule for irritable bowel syndrome with constipation (IBS-C) and chronic constipation. It works directly in the gut to increase fluid secretion (softening stool) and reduce the abdominal pain and bloating that characterise IBS. Because it barely enters the bloodstream, it acts almost entirely within the intestine with minimal whole-body side effects.
453 published studies: 317 human, 16 animal, 14 in-vitro, 181 reviews
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation.
In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Linaclotide works on the inner lining of the intestine in two ways. First, it activates receptors (GC-C) that trigger chloride and water secretion into the gut, softening stool and accelerating transit. Second, the same signalling pathway reduces the sensitivity of pain-sensing nerves in the gut wall, decreasing the visceral hypersensitivity that causes abdominal pain in IBS. Because the peptide is broken down in the gut and barely enters the bloodstream, systemic side effects are minimal — the main side effect is diarrhoea, which is essentially the intended mechanism working too effectively.
Clinical trials showed that about 34% of IBS-C patients met the combined improvement endpoint (reduced pain and improved bowel function) compared to 17% on placebo. The dual mechanism — both increasing fluid secretion and reducing visceral pain sensitivity — distinguishes linaclotide from simple laxatives. Diarrhoea is the most common side effect (approximately 20%) and the main reason patients stop treatment — essentially, the intended mechanism sometimes works too well. The drug carries a boxed warning against use in children under 6 after deaths in young mice, though no such events have occurred in humans. It must be taken on an empty stomach at least 30 minutes before the first meal of the day. Generic availability has improved access. A paediatric approval for functional constipation was recently granted, and there is ongoing research into whether GC-C pathway activation might help prevent colorectal cancer.
"Efficacy and Safety of Linaclotide in Chronic Constipation"
Linaclotide for Colonoscopy Bowel Prep
Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy
A Study of Virtual Reality and Linaclotide for IBS-C
Clinical Study of Bowel Preparation Before Colonoscopy
FDA ORIG 1
EMA Marketing Authorisation
FDA SUPPL 3
FDA SUPPL 2
Health Canada Market Authorisation
FDA SUPPL 5
FDA SUPPL 4
FDA SUPPL 1
FDA SUPPL 6
FDA SUPPL 9
FDA SUPPL 7
FDA SUPPL 8
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 10
FDA SUPPL 13
FDA SUPPL 16
FDA SUPPL 17
FDA SUPPL 18
FDA SUPPL 21
FDA SUPPL 22
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
